Market Overview

Mylan Pharma Wins Final FDA Approval for ANDA for Phenytoin Chewable Tablets, 50 mg

Share:
Related MYL
Biotechs Are Down 17% Since Clinton First Put Industry On Blast Last September
Mylan 'Took The Sting' Out Of The EpiPen Controversy
Healthcare Drug Pricing a Factor for the Market on Wednesday (GuruFocus)
Related PFE
Pfizer's $1.5 Billion Antibiotics Buy: Strategic Long-Term Planning Or Pre-Split Prep?
Risk Arbitrage Trading Strategies
Tight Trading on Thursday with Stocks Ending Lower (GuruFocus)

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Phenytoin Chewable Tablets USP, 50 mg. This product is the generic version of Pfizer's Dilantin® Chewable Tablets, which are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. Phenytoin serum level determinations may be necessary for optimal dosage adjustments.

Posted-In: News FDA

 

Related Articles (MYL + PFE)

View Comments and Join the Discussion!